A global study, led by UCL and UCLH, has shown that the cancer immunotherapy atezolizumab significantly improved the overall survival of advanced stage non-small cell lung cancer patients who were not able to be treated with ...
Jul 6, 2023
1
45
While Immune Checkpoint Inhibitor (ICI) immunotherapy drugs have transformed the treatment of many cancers, some lung cancer patients experience hyperprogression—a paradoxical rapid acceleration of tumor growth—after ...
Apr 28, 2023
0
13
Proteomics is the study and analysis of proteins, including their structures, functions, interactions, and modifications within a biological system. Humans have approximately 20,000 genes that produce over a million different ...
Mar 29, 2023
0
2
Hyaluronan (HA) accumulation is associated with tumorigenesis and aggressive tumor behavior. In a new study, researchers Jun Gong, Michelle Guan, Haesoo Kim, Natalie Moshayedi, Sejal Mehta, Galen Cook-Wiens, Brent K. Larson, ...
Nov 9, 2022
0
2
Early trials of the targeted drug repotrectinib suggest that it could help treat patients with a certain type of non-small cell lung cancer (NSCLC).
Oct 28, 2022
0
11
The U.S. Food and Drug Administration granted regular approval to capmatinib (Tabrecta) for adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a genetic mutation leading to mesenchymal-epithelial ...
Aug 15, 2022
0
6
The use of Stereotactic Body Radiotherapy (SBRT) for patients with non-small cell lung cancer can reduce treatment disparities between White and Black patients, according to research presented today at the IASLC World Conference ...
Aug 8, 2022
0
2
A study presented today at the IASLC World Conference on Lung Cancer 2022 in Vienna disclosed the clinical-relevant intertumoral heterogeneity of non-small cell lung cancer (NSCLC) driven by MET exon 14 skipping.
Aug 8, 2022
0
5
Annual screenings of patients at high risk for lung cancer can catch tumors early and improve a patient's long-term prognosis. However, low-dose computer tomography (LDCT) has a high false-positive rate that can lead to unnecessary ...
Jul 13, 2022
0
5
Nearly 43% of patients with non-small cell lung cancer (NSCLC) whose lung cancers harbored a specific KRAS mutation responded to the experimental drug adagrasib, and the targeted agent also showed activity against lesions ...
Jun 3, 2022
0
2
